Company Monitoring Page for Galapagos

latest headlines for company on cafepharma

Galapagos’ Jyseleca gets UK marketing authorization for ulcerative colitis
Pharmaceutical Business Review
Wed, 01/19/22 - 10:57 am
Tags:
Galapagos, UK, ulcerative colitiis, Jyseleca, filgotinib
Galapagos CEO to retire, though successor yet to be announced
BioPharma Dive
Tue, 08/31/21 - 10:03 pm
Tags:
Galapagos, Pharma CEOs
Galapagos avoids 'complete whiff' as key anti-inflammatory drug fails to beat placebo in midphase trials
Fierce Biotech
Thu, 07/15/21 - 12:25 pm
Tags:
Galapagos, clinical trials, rheumatoid arthritis, ulcerative colitis, psoriasis, filgotinib
Galapagos Touts Positive Post-Hoc Data, but Likely Won’t Gun for US Approval
BioSpace
Mon, 07/12/21 - 11:35 pm
Tags:
Galapagos, ulcerative colitis, filgotinib
Galapagos reports long-awaited safety data for inflammation drug
BioPharma Dive
Thu, 03/4/21 - 11:26 pm
Tags:
Galapagos, inflammation, clinical trials, filgotinib
Gilead's $5B Galapagos black hole widens as pair toss out phase 3 asset after flop
Fierce Biotech
Wed, 02/10/21 - 10:29 am
Tags:
Gilead Sciences, Galapagos, IPF, ziritaxestat
Gilead downsizes multibillion-dollar deal once at center of CEO's rebuild
Bizjournals
Tue, 12/15/20 - 08:31 pm
Tags:
Gilead Sciences, Galapagos, clinical trials, filgotinib, rheumatoid arthritis, inflammatory bowel disease
Galapagos “win” highlights crowded idiopathic pulmonary fibrosis pipeline
EP Vantage
Fri, 12/4/20 - 10:48 am
Tags:
Galapagos, GLPG1205, idiopathic pulmonary fibrosis, clinical trials
Galapagos' osteoarthritis drug flunks phase 2, dashing hopes of $250M Gilead deal
Fierce Biotech
Fri, 10/16/20 - 11:11 am
Tags:
Galapagos, Servier, GLPG1972, osteoarthritis of the knee, clinical trials
Gilead and Galapagos's filgotinib shows sustained efficacy in ulcerative colitis study
Seeking Alpha
Tue, 10/13/20 - 11:17 am
Tags:
filgotinib, Gilead Sciences, Galapagos, clinical trials, ulcerative colitis
Go or no go? Valuable drugs set for FDA decisions
EP Vantage
Wed, 07/29/20 - 10:54 am
Tags:
FDA, drug approvals, Novartis, inclisiran, Biomarin, valrox, Roche, risdiplam, GSK, belantamab mafodotin, Gilead Sciences, Galapagos, filgotinib
3 Biotech Stocks With Big Incoming Catalysts
Motley Fool
Sat, 07/25/20 - 02:25 pm
Tags:
FDA, GW Pharma, Epidiolex, filgotinib, Galapagos, Biomarin, valoctocogene roxaparvovec
Go or no go? Pandemic looms over FDA timelines
EP Vantage
Wed, 07/1/20 - 10:54 am
Tags:
Jazz Pharma, Gilead Sciences, Galapagos, GSK, FDA, pandemic, COVID-19
Gilead builds case for filgotinib in active psoriatic arthritis
Fierce Biotech
Mon, 06/8/20 - 10:38 am
Tags:
Gilead Sciences, Galapagos, filgotinib, clinical trials, psoriatic arthritis
Gilead shows durability of filgotinib ahead of face-off with AbbVie
Fierce Biotech
Thu, 06/4/20 - 11:00 am
Tags:
Gilead Sciences, Galapagos, clinical trials, filgotinib, rheumatoid arthritis
Galapagos finds little comfort in safety
EP Vantage
Fri, 05/22/20 - 10:28 am
Tags:
Galapagos, filgotinib, ulcerative colitis
Gilead's filgotinib phase 3 hits primary endpoint but details dampen hopes
Fierce Biotech
Thu, 05/21/20 - 10:28 am
Tags:
Gilead Sciences, Galapagos, filgotinib, ulcerative colitis, clinical trials
Big pharma heads towards important readouts
EP Vantage
Wed, 05/20/20 - 10:22 am
Tags:
Ozempic, Novo Nordisk, etrolizumab, Roche, Ipatasertib, finerenone, Bayer, filgotinib, Gilead Sciences, Galapagos, Avalglucosidase alfa, Sanofi, Rinvoq, AbbVie, clinical trials
Galapagos CEO talks next steps as coronavirus stalls the biotech's top drug
BioPharma Dive
Wed, 03/25/20 - 11:41 pm
Tags:
Galapagos, Gilead Sciences, filgotinib, rheumatoid arthritis, FDA, COVID-19
Lilly, Galapagos halt trials as coronavirus deepens impact on drug research
BioPharma Dive
Mon, 03/23/20 - 12:00 pm
Tags:
Eli Lilly, Galapagos, ObsEva, clinical trials, COVID-19

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.